Literature DB >> 27377999

Objective assessment of trismus in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT).

Adepitan A Owosho1, Luciana M Pedreira Ramalho2, Haley I Rosenberg1, SaeHee K Yom1, Esther Drill3, Elyn Riedel3, C Jillian Tsai4, Nancy Y Lee4, Joseph M Huryn1, Cherry L Estilo5.   

Abstract

PURPOSE: The aim of this study was to estimate the prevalence of trismus in oral and oropharyngeal cancer patients (OOPC) treated with intensity-modulated radiation therapy (IMRT) and to identify the role of risk factors in patients who developed trismus.
MATERIALS AND METHODS: A retrospective cohort study of OOPC treated with IMRT in our institution from 2009 to 2014 was performed. Patients eligible for this study had pre-RT and post-RT maximal inter-incisal opening (MIO) measurements at 6-48 months post-RT, treated with high-dose radiation (≥60 Gy) and pre-RT MIO ≥36 mm. A descriptive analysis to identify the incidence of trismus, with trismus stated as MIO ≤35 mm at or after 6 months post-RT measurement was performed. The role of risk factors such as age, gender, tumor site, tumor size (T), tumor stage, pre-RT MIO measurements and radiation dose to the tumor were assessed using Fisher exact test and the radiation doses to the ipsilateral muscles of mastication in patients who developed trismus were assessed by matching with control (non-trismus) patients using Wilcoxon Signed Rank test.
RESULTS: The study consisted of 54 patients with a median age of 55 years and 81% were males. The median follow-up time was 10 months. The prevalence of trismus was 14.8%. Patients with pre-RT MIO measurements ≤40 mm were at risk of developing trismus (P < 0.001). In trismus patients, the average mean radiation dose to the masseter and medial pterygoid muscles was numerically higher but not significantly different (P = 0.08; P = 0.22, respectively) to matched control patients. Age, gender, radiation dose to the tumor, tumor site, size (T) and stage were also found to be not significant.
CONCLUSION: Pre-RT MIO measurement was a significant risk factor for the development of trismus. However, this is a non-modifiable factor. Limiting radiation dose to the muscles of mastication could prevent this complication.
Copyright © 2016 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Intensity-modulated radiation therapy; Oral cancer; Oropharyngeal cancer; Trismus

Mesh:

Year:  2016        PMID: 27377999      PMCID: PMC5279066          DOI: 10.1016/j.jcms.2016.06.008

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  28 in total

Review 1.  Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls.

Authors:  William M Mendenhall; Robert J Amdur; Jatinder R Palta
Journal:  J Clin Oncol       Date:  2006-06-10       Impact factor: 44.544

2.  Limited mouth opening after primary therapy of head and neck cancer.

Authors:  Clemens Weber; Steffen Dommerich; Hans Wilhelm Pau; Burkhard Kramp
Journal:  Oral Maxillofac Surg       Date:  2010-09

Review 3.  A systematic review of trismus induced by cancer therapies in head and neck cancer patients.

Authors:  Rene-Jean Bensadoun; Dorothea Riesenbeck; Peter B Lockhart; Linda S Elting; Fred K L Spijkervet; Mike T Brennan
Journal:  Support Care Cancer       Date:  2010-03-06       Impact factor: 3.603

4.  Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience.

Authors:  Jeremy Setton; Nicola Caria; Jonathan Romanyshyn; Lawrence Koutcher; Suzanne L Wolden; Michael J Zelefsky; Nicholas Rowan; Eric J Sherman; Matthew G Fury; David G Pfister; Richard J Wong; Jatin P Shah; Dennis H Kraus; Weiji Shi; Zhigang Zhang; Karen D Schupak; Daphna Y Gelblum; Shyam D Rao; Nancy Y Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-12-16       Impact factor: 7.038

5.  Mouth opening and trismus in patients undergoing curative treatment for head and neck cancer.

Authors:  F Steiner; J Evans; R Marsh; P Rigby; S James; K Sutherland; R Wickens; N Nedev; B Kelly; S T Tan
Journal:  Int J Oral Maxillofac Surg       Date:  2015-01-07       Impact factor: 2.789

6.  Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers.

Authors:  Daniel R Gomez; Joanne E Zhung; Jennifer Gomez; Kelvin Chan; Abraham J Wu; Suzanne L Wolden; David G Pfister; Ashok Shaha; Jatin P Shah; Dennis H Kraus; Richard J Wong; Nancy Y Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-08-15       Impact factor: 7.038

7.  Trismus in patients with malignant tumours in the head and neck.

Authors:  K Ichimura; T Tanaka
Journal:  J Laryngol Otol       Date:  1993-11       Impact factor: 1.469

8.  Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.

Authors:  Marije R Vergeer; Patricia A H Doornaert; Derek H F Rietveld; C René Leemans; Ben J Slotman; Johannes A Langendijk
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-26       Impact factor: 7.038

9.  Exercise adherence in patients with trismus due to head and neck oncology: a qualitative study into the use of the Therabite.

Authors:  L J Melchers; E Van Weert; C H G Beurskens; H Reintsema; A P Slagter; J L N Roodenburg; P U Dijkstra
Journal:  Int J Oral Maxillofac Surg       Date:  2009-05-02       Impact factor: 2.789

10.  Radiation-induced trismus in the ARTSCAN head and neck trial.

Authors:  Ulrika Lindblom; Ola Gärskog; Elisabeth Kjellén; Göran Laurell; Eva Levring Jäghagen; Peter Wahlberg; Björn Zackrisson; Per Nilsson
Journal:  Acta Oncol       Date:  2014-03-26       Impact factor: 4.089

View more
  4 in total

1.  Trends in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma Incidence, Vermont 1999-2013.

Authors:  Adepitan A Owosho; Rashidah Wiley; Tessie Stansbury; Semiu O Gbadamosi; Jon S Ryder
Journal:  J Community Health       Date:  2018-08

2.  European white paper: oropharyngeal dysphagia in head and neck cancer.

Authors:  Laura W J Baijens; Margaret Walshe; Leena-Maija Aaltonen; Christoph Arens; Reinie Cordier; Patrick Cras; Lise Crevier-Buchman; Chris Curtis; Wojciech Golusinski; Roganie Govender; Jesper Grau Eriksen; Kevin Hansen; Kate Heathcote; Markus M Hess; Sefik Hosal; Jens Peter Klussmann; C René Leemans; Denise MacCarthy; Beatrice Manduchi; Jean-Paul Marie; Reza Nouraei; Claire Parkes; Christina Pflug; Walmari Pilz; Julie Regan; Nathalie Rommel; Antonio Schindler; Annemie M W J Schols; Renee Speyer; Giovanni Succo; Irene Wessel; Anna C H Willemsen; Taner Yilmaz; Pere Clavé
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-12-19       Impact factor: 2.503

3.  Comparison of mean radiation dose and dosimetric distribution to tooth-bearing regions of the mandible associated with proton beam radiation therapy and intensity-modulated radiation therapy for ipsilateral head and neck tumor.

Authors:  Adepitan A Owosho; SaeHee K Yom; Zhiqiang Han; Kevin Sine; Nancy Y Lee; Joseph M Huryn; Cherry L Estilo
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2016-07-19

4.  The Effectiveness of Surgical Methods for Trismus Release at Least 6 Months After Head and Neck Cancer Treatment: Systematic Review.

Authors:  Maximiliaan Smeets; Tomas-Marijn Croonenborghs; Jeroen Van Dessel; Constantinus Politis; Reinhilde Jacobs; Michel Bila
Journal:  Front Oral Health       Date:  2022-01-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.